Heidi M. De Gruyter
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Structural insights into MERS and SARS coronavirus membrane proteins.
Journal: Communications biology
Published: April 07, 2025
A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein.
Journal: Nature
Published: February 21, 2024
Deubiquitinating activity of SARS-CoV-2 papain-like protease does not influence virus replication or innate immune responses in vivo.
Journal: PLoS pathogens
Published: January 19, 2024
The Main Protease of Middle East Respiratory Syndrome Coronavirus Induces Cleavage of Mitochondrial Antiviral Signaling Protein to Antagonize the Innate Immune Response.
Journal: Viruses
Published: December 21, 2023
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: November 13, 2023
Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
Journal: Journal of virology
Published: August 18, 2016
Induction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine.
Journal: Emerging infectious diseases
Published: May 20, 2015
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Journal: The Lancet. Infectious diseases
Published: December 03, 2014
A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.
Journal: The Journal of infectious diseases
Published: September 24, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026